In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.
In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, oncology pharmacist at Corewell Health William Beaumont University Hospital, discusses the expanding range of bladder-preserving treatments for non–muscle-invasive bladder cancer (NMIBC), while emphasizing that BCG is an important standard when administered at the appropriate dose and schedule.
